Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
NCT ID: NCT00536796
Last Updated: 2014-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1096 participants
OBSERVATIONAL
2007-09-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
NCT00536965
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
NCT00327691
Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)
NCT00723723
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136
An ADME Study of [14C]AZD0780 in Healthy Male Subjects
NCT05817461
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients at very high risk
No interventions assigned to this group
Patients at high risk
No interventions assigned to this group
Patients at medium risk
No interventions assigned to this group
Patients at low risk
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Josef Patsch, MD
Role: STUDY_CHAIR
Chair of the Austrian Atheroslerosis Society
Bernhard Foger, MD
Role: STUDY_CHAIR
Co-Chair of the Austrian Atheroslerosis Society
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Rohrbach, Upper Austria, Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-CAT-CRE-2007/2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.